TORNTPHARM
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
SA's Competition Commission Approves Proposed Torrent Pharmaceuticals/ JB Pharma Deal, With Conditions
Sept 25 (Reuters) - SA's Competition Commission :
SA'S COMPETITION COMMISSION : RECOMMENDS COMPETITION TRIBUNAL APPROVE TOYOTA FUDSON & TOYOTA MOTOR DEAL TO BUY TOYOTA INDUSTRIES , WITHOUT CONDITIONS
SA'S COMPETITION COMMISSION : APPROVED PROPOSED TRANSACTION WHEREBY TORRENT PHARMACEUTICALS INTENDS TO BUY JB PHARMA, WITH CONDITIONS
Further company coverage: 6201.T
(([email protected];))
Sept 25 (Reuters) - SA's Competition Commission :
SA'S COMPETITION COMMISSION : RECOMMENDS COMPETITION TRIBUNAL APPROVE TOYOTA FUDSON & TOYOTA MOTOR DEAL TO BUY TOYOTA INDUSTRIES , WITHOUT CONDITIONS
SA'S COMPETITION COMMISSION : APPROVED PROPOSED TRANSACTION WHEREBY TORRENT PHARMACEUTICALS INTENDS TO BUY JB PHARMA, WITH CONDITIONS
Further company coverage: 6201.T
(([email protected];))
Torrent Pharma Issued Commercial Papers For An Amount Of 2 Billion Rupees
Sept 24 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
TORRENT PHARMA - ISSUED COMMERCIAL PAPERS FOR AN AMOUNT OF 2 BILLION RUPEES
Source text: ID:nnAZN4KJ6P6
Further company coverage: TORP.NS
(([email protected];))
Sept 24 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
TORRENT PHARMA - ISSUED COMMERCIAL PAPERS FOR AN AMOUNT OF 2 BILLION RUPEES
Source text: ID:nnAZN4KJ6P6
Further company coverage: TORP.NS
(([email protected];))
Torrent Pharmaceuticals To Buy Controlling Stake In J. B. Chemicals
Sept 23 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
TO BUY CONTROLLING STAKE IN J. B. CHEMICALS
COMPETITION COMMISSION, SOUTH AFRICA APPROVES CO TO ACQUIRE STAKE IN J. B. CHEMICALS
Source text: ID:nBSE6GP2bl
Further company coverage: TORP.NS
(([email protected];;))
Sept 23 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
TO BUY CONTROLLING STAKE IN J. B. CHEMICALS
COMPETITION COMMISSION, SOUTH AFRICA APPROVES CO TO ACQUIRE STAKE IN J. B. CHEMICALS
Source text: ID:nBSE6GP2bl
Further company coverage: TORP.NS
(([email protected];;))
Torrent Pharma Issues Commercial Papers For 2 Billion Rupees
Sept 17 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
TORRENT PHARMA - ISSUED COMMERCIAL PAPERS FOR AN AMOUNT OF 2 BILLION RUPEES
Source text: ID:nNSE7WpRbJ
Further company coverage: TORP.NS
(([email protected];;))
Sept 17 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
TORRENT PHARMA - ISSUED COMMERCIAL PAPERS FOR AN AMOUNT OF 2 BILLION RUPEES
Source text: ID:nNSE7WpRbJ
Further company coverage: TORP.NS
(([email protected];;))
Health Rounds: Clopidogrel better than aspirin for preventing heart attacks and strokes
This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up here
By Nancy Lapid
Sept 3 (Reuters) - The commonly prescribed blood thinner clopidogrel should replace aspirin as a routine pill for preventing heart attacks and strokes in people who already have at least some degree of heart disease, researchers reported at the European Society of Cardiology Congress.
Pooled data on nearly 29,000 patients with coronary artery disease who had participated in seven earlier randomized trials showed that those taking clopidogrel had a 14% lower risk of major adverse cardiovascular or cerebrovascular events, including heart attack, stroke, or cardiovascular death, compared to those taking aspirin, during an average follow-up of 5.5 years.
“These results suggest that clopidogrel should be considered the preferred long-term antiplatelet medication for patients with established coronary artery disease,” the researchers said.
Clopidogrel is the generic name of the widely used blood clot preventer Plavix, sold by Bristol Myers Squibb BMY.N and Sanofi SASY.PA. Several companies sell generic clopidogrel including Aurobindo Pharma ARBN.NS, Sun Pharma SUN.NS and Teva Pharmaceuticals TEVA.TA.
Rates of anticoagulant-related side effects like ulcers and major bleeding were similar between the two drugs, dispelling concerns that clopidogrel might lead to more bleeding complications, the researchers said.
The researchers said their analysis included many types of patients and subgroups to ensure the findings, which were also published in The Lancet, applied broadly.
“Even patients who might respond less well to clopidogrel due to genetic or clinical factors still benefited from its use over aspirin,” the researchers said in a statement.
Because clopidogrel is widely available and inexpensive, the study’s findings have the potential to influence clinical guidelines worldwide and improve patient outcomes, the researchers said.
RECYCLED PACEMAKERS IMPROVE ACCESS IN LOW-INCOME NATIONS
Cardiac pacemaker devices can be reconditioned to provide new hope for patients in low- and middle-income countries, researchers said at the ESC meeting in Madrid.
In Kenya, Mexico, Mozambique, Nigeria, Paraguay, Sierra Leone and Venezuela, 306 patients with a life expectancy of at least two years, a clear medical need for pacemaker therapy and no financial means to acquire one were randomly assigned to receive a reconditioned pacemaker or a new pacemaker.
The researchers’ primary concern was that reconditioned devices, which had been removed from other patients, might transmit infections when re-implanted.
A year after the pacemakers were implanted, the incidence of procedure-related infections was 1.6% for those in the reconditioned pacemaker group and 3.1% for those who got new devices. The results demonstrate that the older devices were non-inferior to new ones, the researchers said in a statement.
There were no device malfunctions in either group.
The study was conducted by doctors at the University of Michigan-based Project My Heart Your Heart, which collects pacemakers removed from cadavers by funeral directors.
“Patients in many low- and middle-income countries still have very limited access to cardiac pacing despite its routine use in higher-income countries,” study leader Dr. Thomas Crawford from the University of Michigan said in a statement.
“Indeed, access to pacemaker implantation is around 200-fold lower in Africa than in Europe," Crawford said.
Project My Heart Your Heart developed a comprehensive protocol for cleaning, functional testing and sterilizing reconditioned devices, and has U.S. approval for their export to countries whose governments have provided permission for pacemaker importation, he added.
(To receive the full newsletter in your inbox for free sign up here)
(Reporting by Nancy Lapid; Editing by Bill Berkrot)
This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up here
By Nancy Lapid
Sept 3 (Reuters) - The commonly prescribed blood thinner clopidogrel should replace aspirin as a routine pill for preventing heart attacks and strokes in people who already have at least some degree of heart disease, researchers reported at the European Society of Cardiology Congress.
Pooled data on nearly 29,000 patients with coronary artery disease who had participated in seven earlier randomized trials showed that those taking clopidogrel had a 14% lower risk of major adverse cardiovascular or cerebrovascular events, including heart attack, stroke, or cardiovascular death, compared to those taking aspirin, during an average follow-up of 5.5 years.
“These results suggest that clopidogrel should be considered the preferred long-term antiplatelet medication for patients with established coronary artery disease,” the researchers said.
Clopidogrel is the generic name of the widely used blood clot preventer Plavix, sold by Bristol Myers Squibb BMY.N and Sanofi SASY.PA. Several companies sell generic clopidogrel including Aurobindo Pharma ARBN.NS, Sun Pharma SUN.NS and Teva Pharmaceuticals TEVA.TA.
Rates of anticoagulant-related side effects like ulcers and major bleeding were similar between the two drugs, dispelling concerns that clopidogrel might lead to more bleeding complications, the researchers said.
The researchers said their analysis included many types of patients and subgroups to ensure the findings, which were also published in The Lancet, applied broadly.
“Even patients who might respond less well to clopidogrel due to genetic or clinical factors still benefited from its use over aspirin,” the researchers said in a statement.
Because clopidogrel is widely available and inexpensive, the study’s findings have the potential to influence clinical guidelines worldwide and improve patient outcomes, the researchers said.
RECYCLED PACEMAKERS IMPROVE ACCESS IN LOW-INCOME NATIONS
Cardiac pacemaker devices can be reconditioned to provide new hope for patients in low- and middle-income countries, researchers said at the ESC meeting in Madrid.
In Kenya, Mexico, Mozambique, Nigeria, Paraguay, Sierra Leone and Venezuela, 306 patients with a life expectancy of at least two years, a clear medical need for pacemaker therapy and no financial means to acquire one were randomly assigned to receive a reconditioned pacemaker or a new pacemaker.
The researchers’ primary concern was that reconditioned devices, which had been removed from other patients, might transmit infections when re-implanted.
A year after the pacemakers were implanted, the incidence of procedure-related infections was 1.6% for those in the reconditioned pacemaker group and 3.1% for those who got new devices. The results demonstrate that the older devices were non-inferior to new ones, the researchers said in a statement.
There were no device malfunctions in either group.
The study was conducted by doctors at the University of Michigan-based Project My Heart Your Heart, which collects pacemakers removed from cadavers by funeral directors.
“Patients in many low- and middle-income countries still have very limited access to cardiac pacing despite its routine use in higher-income countries,” study leader Dr. Thomas Crawford from the University of Michigan said in a statement.
“Indeed, access to pacemaker implantation is around 200-fold lower in Africa than in Europe," Crawford said.
Project My Heart Your Heart developed a comprehensive protocol for cleaning, functional testing and sterilizing reconditioned devices, and has U.S. approval for their export to countries whose governments have provided permission for pacemaker importation, he added.
(To receive the full newsletter in your inbox for free sign up here)
(Reporting by Nancy Lapid; Editing by Bill Berkrot)
Health Rounds: Clopidogrel better than aspirin for preventing heart attacks and strokes
Health Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us? Forward this newsletter to them. They can also subscribe here
By Nancy Lapid
Sept 2 (Reuters) - Hello Health Rounds readers! Today we highlight two studies presented at the European Society of Cardiology meeting in Madrid, one that compared widely used blood thinners for preventing serious heart problems, and one that tested the safety of reusing cardiac pacemakers.
Clopidogrel tops aspirin for routine use in heart patients
The commonly prescribed blood thinner clopidogrel should replace aspirin as a routine pill for preventing heart attacks and strokes in people who already have at least some degree of heart disease, researchers reported at the European Society of Cardiology Congress.
Pooled data on nearly 29,000 patients with coronary artery disease who had participated in seven earlier randomized trials showed that those taking clopidogrel had a 14% lower risk of major adverse cardiovascular or cerebrovascular events, including heart attack, stroke, or cardiovascular death, compared to those taking aspirin, during an average follow-up of 5.5 years.
“These results suggest that clopidogrel should be considered the preferred long-term antiplatelet medication for patients with established coronary artery disease,” the researchers said.
Clopidogrel is the generic name of the widely used blood clot preventer Plavix, sold by Bristol Myers Squibb BMY.N and Sanofi SASY.PA. Several companies sell generic clopidogrel including Aurobindo Pharma ARBN.NS, Sun Pharma SUN.NS and Teva Pharmaceuticals TEVA.TA.
Rates of anticoagulant-related side effects like ulcers and major bleeding were similar between the two drugs, dispelling concerns that clopidogrel might lead to more bleeding complications, the researchers said.
The researchers said their analysis included many types of patients and subgroups to ensure the findings, which were also published in The Lancet, applied broadly.
“Even patients who might respond less well to clopidogrel due to genetic or clinical factors still benefited from its use over aspirin,” the researchers said in a statement.
Because clopidogrel is widely available and inexpensive, the study’s findings have the potential to influence clinical guidelines worldwide and improve patient outcomes, the researchers said.
Recycled pacemakers improve access in low-income nations
Cardiac pacemaker devices can be reconditioned to provide new hope for patients in low- and middle-income countries, researchers said at the ESC meeting in Madrid.
In Kenya, Mexico, Mozambique, Nigeria, Paraguay, Sierra Leone and Venezuela, 306 patients with a life expectancy of at least two years, a clear medical need for pacemaker therapy and no financial means to acquire one were randomly assigned to receive a reconditioned pacemaker or a new pacemaker.
The researchers’ primary concern was that reconditioned devices, which had been removed from other patients, might transmit infections when re-implanted.
A year after the pacemakers were implanted, the incidence of procedure-related infections was 1.6% for those in the reconditioned pacemaker group and 3.1% for those who got new devices. The results demonstrate that the older devices were non-inferior to new ones, the researchers said in a statement.
There were no device malfunctions in either group.
The study was conducted by doctors at the University of Michigan-based Project My Heart Your Heart, which collects pacemakers removed from cadavers by funeral directors.
“Patients in many low- and middle-income countries still have very limited access to cardiac pacing despite its routine use in higher-income countries,” study leader Dr. Thomas Crawford from the University of Michigan said in a statement.
“Indeed, access to pacemaker implantation is around 200-fold lower in Africa than in Europe," Crawford said.
Project My Heart Your Heart developed a comprehensive protocol for cleaning, functional testing and sterilizing reconditioned devices, and has U.S. approval for their export to countries whose governments have provided permission for pacemaker importation, he added.
(Reporting by Nancy Lapid; Editing by Bill Berkrot)
Health Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us? Forward this newsletter to them. They can also subscribe here
By Nancy Lapid
Sept 2 (Reuters) - Hello Health Rounds readers! Today we highlight two studies presented at the European Society of Cardiology meeting in Madrid, one that compared widely used blood thinners for preventing serious heart problems, and one that tested the safety of reusing cardiac pacemakers.
Clopidogrel tops aspirin for routine use in heart patients
The commonly prescribed blood thinner clopidogrel should replace aspirin as a routine pill for preventing heart attacks and strokes in people who already have at least some degree of heart disease, researchers reported at the European Society of Cardiology Congress.
Pooled data on nearly 29,000 patients with coronary artery disease who had participated in seven earlier randomized trials showed that those taking clopidogrel had a 14% lower risk of major adverse cardiovascular or cerebrovascular events, including heart attack, stroke, or cardiovascular death, compared to those taking aspirin, during an average follow-up of 5.5 years.
“These results suggest that clopidogrel should be considered the preferred long-term antiplatelet medication for patients with established coronary artery disease,” the researchers said.
Clopidogrel is the generic name of the widely used blood clot preventer Plavix, sold by Bristol Myers Squibb BMY.N and Sanofi SASY.PA. Several companies sell generic clopidogrel including Aurobindo Pharma ARBN.NS, Sun Pharma SUN.NS and Teva Pharmaceuticals TEVA.TA.
Rates of anticoagulant-related side effects like ulcers and major bleeding were similar between the two drugs, dispelling concerns that clopidogrel might lead to more bleeding complications, the researchers said.
The researchers said their analysis included many types of patients and subgroups to ensure the findings, which were also published in The Lancet, applied broadly.
“Even patients who might respond less well to clopidogrel due to genetic or clinical factors still benefited from its use over aspirin,” the researchers said in a statement.
Because clopidogrel is widely available and inexpensive, the study’s findings have the potential to influence clinical guidelines worldwide and improve patient outcomes, the researchers said.
Recycled pacemakers improve access in low-income nations
Cardiac pacemaker devices can be reconditioned to provide new hope for patients in low- and middle-income countries, researchers said at the ESC meeting in Madrid.
In Kenya, Mexico, Mozambique, Nigeria, Paraguay, Sierra Leone and Venezuela, 306 patients with a life expectancy of at least two years, a clear medical need for pacemaker therapy and no financial means to acquire one were randomly assigned to receive a reconditioned pacemaker or a new pacemaker.
The researchers’ primary concern was that reconditioned devices, which had been removed from other patients, might transmit infections when re-implanted.
A year after the pacemakers were implanted, the incidence of procedure-related infections was 1.6% for those in the reconditioned pacemaker group and 3.1% for those who got new devices. The results demonstrate that the older devices were non-inferior to new ones, the researchers said in a statement.
There were no device malfunctions in either group.
The study was conducted by doctors at the University of Michigan-based Project My Heart Your Heart, which collects pacemakers removed from cadavers by funeral directors.
“Patients in many low- and middle-income countries still have very limited access to cardiac pacing despite its routine use in higher-income countries,” study leader Dr. Thomas Crawford from the University of Michigan said in a statement.
“Indeed, access to pacemaker implantation is around 200-fold lower in Africa than in Europe," Crawford said.
Project My Heart Your Heart developed a comprehensive protocol for cleaning, functional testing and sterilizing reconditioned devices, and has U.S. approval for their export to countries whose governments have provided permission for pacemaker importation, he added.
(Reporting by Nancy Lapid; Editing by Bill Berkrot)
India's Torrent Pharma climbs on strong quarterly results
** Shares of Torrent Pharma TORP.NS climb 2.1% to 3,697.8 rupees
** Drugmaker's Q1 consol net profit rose 20% y/y on strong demand for drugs used to treat long-term conditions
** At least 10 brokerages increased PTs after results, raising median PT to 3,800 rupees from 3,580 rupees last month, as per data compiled by LSEG
** HSBC says continued traction in TORP's India and Brazil segments, a pick-up in sales in the U.S. to support a healthy EBITDA margin outlook
** Adds, co expects EBITDA margins of at least 32.9% for the remaining quarters of FY26; its operating EBITDA margins stood at 32.5% in Q1
** Jefferies expects TORP's India, Brazil sales to continue outperforming, while losses in U.S. likely to reduce through fiscal year
** TORP up ~8% YTD, as of Monday's close
(Reporting by Manvi Pant in Bengaluru)
(([email protected]; +918447554364;))
** Shares of Torrent Pharma TORP.NS climb 2.1% to 3,697.8 rupees
** Drugmaker's Q1 consol net profit rose 20% y/y on strong demand for drugs used to treat long-term conditions
** At least 10 brokerages increased PTs after results, raising median PT to 3,800 rupees from 3,580 rupees last month, as per data compiled by LSEG
** HSBC says continued traction in TORP's India and Brazil segments, a pick-up in sales in the U.S. to support a healthy EBITDA margin outlook
** Adds, co expects EBITDA margins of at least 32.9% for the remaining quarters of FY26; its operating EBITDA margins stood at 32.5% in Q1
** Jefferies expects TORP's India, Brazil sales to continue outperforming, while losses in U.S. likely to reduce through fiscal year
** TORP up ~8% YTD, as of Monday's close
(Reporting by Manvi Pant in Bengaluru)
(([email protected]; +918447554364;))
Torrent Pharma Q1 Consol Net Profit 5.48 Billion Rupees
July 28 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
Q1 CONSOL NET PROFIT 5.48 BILLION RUPEES
Q1 CONSOL TOTAL REVENUE FROM OPERATIONS 31.78 BILLION RUPEES; IBES EST 31.57 BILLION RUPEES
Further company coverage: TORP.NS
(([email protected];))
July 28 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
Q1 CONSOL NET PROFIT 5.48 BILLION RUPEES
Q1 CONSOL TOTAL REVENUE FROM OPERATIONS 31.78 BILLION RUPEES; IBES EST 31.57 BILLION RUPEES
Further company coverage: TORP.NS
(([email protected];))
Torrent Pharmaceuticals To Consider Debenture/Bond Issuance
July 21 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
BOARD TO CONSIDER DEBENTURE/BOND ISSUANCE
TO CONSIDER ISSUE VIA PRIVATE PLACEMENT
Source text: ID:nBSE3p8mYb
Further company coverage: TORP.NS
(([email protected];;))
July 21 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
BOARD TO CONSIDER DEBENTURE/BOND ISSUANCE
TO CONSIDER ISSUE VIA PRIVATE PLACEMENT
Source text: ID:nBSE3p8mYb
Further company coverage: TORP.NS
(([email protected];;))
Torrent Pharma Agrees To Buy Further 2.41% Stake Of J.B. Chemicals For 6.2 Billion Rupees
July 3 (Reuters) - J B Chemicals and Pharmaceuticals Ltd JBCH.NS:
AGREES TO BUY FURTHER 2.41% STAKE OF J.B. CHEMICALS FOR ABOUT 6.2 BILLION RUPEES
Source text: ID:nBSE82mH2n
Further company coverage: JBCH.NS
(([email protected];))
July 3 (Reuters) - J B Chemicals and Pharmaceuticals Ltd JBCH.NS:
AGREES TO BUY FURTHER 2.41% STAKE OF J.B. CHEMICALS FOR ABOUT 6.2 BILLION RUPEES
Source text: ID:nBSE82mH2n
Further company coverage: JBCH.NS
(([email protected];))
PRESS DIGEST- Wall Street Journal - June 30
June 30 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.
- Canada scrapped its digital services tax targeting U.S. technology firms late on Sunday, just hours before it was due to take effect, in a bid to advance stalled trade negotiations with the United States.
- ASL Strategic Value Fund plans to push shareholders of drugmaker Avadel Pharmaceuticals AVDL.O to vote to remove the company's board, citing mismanagement in the launch of its flagship sleep disorder drug.
- India's Torrent Pharmaceuticals TORP.NS will acquire a 46.39% controlling stake in smaller peer JB Chemicals and Pharmaceuticals JBCH.NS from New York-based investment firm KKR KKR.N.
- Two firefighters were shot dead while responding to a fire in northern Idaho and the body of a man was later found with a gun nearby, the Kootenai County Sheriff's Office said on Sunday, as it lifted a shelter-in-place order.
- Public calls for lower interest rates of the kind directed by President Trump toward Federal Reserve Chair Jerome Powell are not a threat to the central bank's independence, the Bank for International Settlements said Sunday.
(Compiled by Bengaluru newsroom)
June 30 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.
- Canada scrapped its digital services tax targeting U.S. technology firms late on Sunday, just hours before it was due to take effect, in a bid to advance stalled trade negotiations with the United States.
- ASL Strategic Value Fund plans to push shareholders of drugmaker Avadel Pharmaceuticals AVDL.O to vote to remove the company's board, citing mismanagement in the launch of its flagship sleep disorder drug.
- India's Torrent Pharmaceuticals TORP.NS will acquire a 46.39% controlling stake in smaller peer JB Chemicals and Pharmaceuticals JBCH.NS from New York-based investment firm KKR KKR.N.
- Two firefighters were shot dead while responding to a fire in northern Idaho and the body of a man was later found with a gun nearby, the Kootenai County Sheriff's Office said on Sunday, as it lifted a shelter-in-place order.
- Public calls for lower interest rates of the kind directed by President Trump toward Federal Reserve Chair Jerome Powell are not a threat to the central bank's independence, the Bank for International Settlements said Sunday.
(Compiled by Bengaluru newsroom)
Torrent Pharma To Acquire Controlling Stake In J. B. Chemicals & Pharmaceuticals From KKR
June 29 (Reuters) - KKR & Co Inc KKR.N:
TORRENT PHARMA TO ACQUIRE CONTROLLING STAKE IN J. B. CHEMICALS & PHARMACEUTICALS FROM KKR
KKR & CO INC - TORRENT TO BUY 46.39% STAKE IN JB PHARMA FOR INR 11,917 CRORES
KKR & CO INC - DEAL VALUED AT INR 25,689 CRORES
KKR & CO INC - TORRENT INTENDS TO BUY ADDITIONAL 2.80% EQUITY SHARES
KKR & CO INC - OPEN OFFER PRICE SET AT INR 1,639.18 PER SHARE
KKR & CO INC - JB PHARMA SHAREHOLDERS TO RECEIVE 51 TORRENT SHARES FOR EVERY 100 JB PHARMA SHARES
Source text: ID:nBw7fWkMMa
Further company coverage: KKR.N
(([email protected];))
June 29 (Reuters) - KKR & Co Inc KKR.N:
TORRENT PHARMA TO ACQUIRE CONTROLLING STAKE IN J. B. CHEMICALS & PHARMACEUTICALS FROM KKR
KKR & CO INC - TORRENT TO BUY 46.39% STAKE IN JB PHARMA FOR INR 11,917 CRORES
KKR & CO INC - DEAL VALUED AT INR 25,689 CRORES
KKR & CO INC - TORRENT INTENDS TO BUY ADDITIONAL 2.80% EQUITY SHARES
KKR & CO INC - OPEN OFFER PRICE SET AT INR 1,639.18 PER SHARE
KKR & CO INC - JB PHARMA SHAREHOLDERS TO RECEIVE 51 TORRENT SHARES FOR EVERY 100 JB PHARMA SHARES
Source text: ID:nBw7fWkMMa
Further company coverage: KKR.N
(([email protected];))
Torrent Pharma Issues Commercial Papers For 3 Billion Rupees
June 26 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
TORRENT PHARMA - ISSUED COMMERCIAL PAPERS FOR AN AMOUNT OF 3 BILLION RUPEES
Source text: ID:nBSE5cWXrj
Further company coverage: TORP.NS
(([email protected];;))
June 26 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
TORRENT PHARMA - ISSUED COMMERCIAL PAPERS FOR AN AMOUNT OF 3 BILLION RUPEES
Source text: ID:nBSE5cWXrj
Further company coverage: TORP.NS
(([email protected];;))
Torrent Pharmaceuticals Issues Commercial Papers Worth 2 Billion Rupees
June 20 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
ISSUES COMMERCIAL PAPERS WORTH 2 BILLION RUPEES
Source text: ID:nBSEV7Cdc
Further company coverage: TORP.NS
(([email protected];))
June 20 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
ISSUES COMMERCIAL PAPERS WORTH 2 BILLION RUPEES
Source text: ID:nBSEV7Cdc
Further company coverage: TORP.NS
(([email protected];))
Torrent Pharma Reports Q4 Consol Net Profit Of 4.98 Billion Rupees
May 20 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
Q4 CONSOL NET PROFIT 4.98 BILLION RUPEES; IBES EST 5.19 BILLION RUPEES
Q4 CONSOL TOTAL REVENUE FROM OPERATIONS 29.59 BILLION RUPEES; IBES EST 29.85 BILLION RUPEES
DIVIDEND 6 RUPEES PER SHARE
RECOMMENDED MEMBERS TO OBTAIN ENABLING APPROVAL FOR 50 BLN RUPEES SHARE ISSUANCE
Further company coverage: TORP.NS
(([email protected];))
May 20 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
Q4 CONSOL NET PROFIT 4.98 BILLION RUPEES; IBES EST 5.19 BILLION RUPEES
Q4 CONSOL TOTAL REVENUE FROM OPERATIONS 29.59 BILLION RUPEES; IBES EST 29.85 BILLION RUPEES
DIVIDEND 6 RUPEES PER SHARE
RECOMMENDED MEMBERS TO OBTAIN ENABLING APPROVAL FOR 50 BLN RUPEES SHARE ISSUANCE
Further company coverage: TORP.NS
(([email protected];))
Torrent Pharmaceuticals To Consider Fundraising
May 13 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
TORRENT PHARMACEUTICALS LTD - BOARD TO CONSIDER FUNDRAISING
Source text: ID:nBSE3SfPcz
Further company coverage: TORP.NS
(([email protected];;))
May 13 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
TORRENT PHARMACEUTICALS LTD - BOARD TO CONSIDER FUNDRAISING
Source text: ID:nBSE3SfPcz
Further company coverage: TORP.NS
(([email protected];;))
Torrent Pharmaceuticals Issues 2 Billion Rupees Commercial Papers
March 26 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
TORRENT PHARMACEUTICALS LTD - ISSUES 2 BILLION RUPEES COMMERCIAL PAPERS
Source text: ID:nBSE27YSlR
Further company coverage: TORP.NS
(([email protected];))
March 26 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
TORRENT PHARMACEUTICALS LTD - ISSUES 2 BILLION RUPEES COMMERCIAL PAPERS
Source text: ID:nBSE27YSlR
Further company coverage: TORP.NS
(([email protected];))
Torrent Pharmaceuticals Issues 3 Billion Rupees Commercial Papers
March 25 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
TORRENT PHARMACEUTICALS LTD - ISSUES 3 BILLION RUPEES COMMERCIAL PAPERS
Source text: ID:nBSE3TY9f0
Further company coverage: TORP.NS
(([email protected];;))
March 25 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
TORRENT PHARMACEUTICALS LTD - ISSUES 3 BILLION RUPEES COMMERCIAL PAPERS
Source text: ID:nBSE3TY9f0
Further company coverage: TORP.NS
(([email protected];;))
India's Torrent Pharmaceuticals gains after quarterly profit jump
** Shares of Torrent Pharmaceuticals TORP.NS rise as much as 3.5% to 3,360.70 rupees
** The pharmaceutical company on Friday reported a 13.5% Y/Y rise in Q3 consol net profit while total rev from ops rose 2.8% Y/Y
** TORP is the only stock in green in the Nifty pharma sub-index .NIPHARM, which is down 2.3%
** Stock currently above 50-day, 100-day and 200-day exponential moving averages
** More than 783,000 shares change hands, 3.1x of 30-day avg
** Avg rating of 26 analysts equivalent of "hold", median PT is 3,584.50 rupees - LSEG data
** Stock rose 45.7% in 2024 vs 39.1% gains by Nifty pharma
(Reporting by Ashish Chandra in Bengaluru)
(([email protected] (+91 7982114624))
** Shares of Torrent Pharmaceuticals TORP.NS rise as much as 3.5% to 3,360.70 rupees
** The pharmaceutical company on Friday reported a 13.5% Y/Y rise in Q3 consol net profit while total rev from ops rose 2.8% Y/Y
** TORP is the only stock in green in the Nifty pharma sub-index .NIPHARM, which is down 2.3%
** Stock currently above 50-day, 100-day and 200-day exponential moving averages
** More than 783,000 shares change hands, 3.1x of 30-day avg
** Avg rating of 26 analysts equivalent of "hold", median PT is 3,584.50 rupees - LSEG data
** Stock rose 45.7% in 2024 vs 39.1% gains by Nifty pharma
(Reporting by Ashish Chandra in Bengaluru)
(([email protected] (+91 7982114624))
Torrent Pharmaceuticals Q3 Consol Net Profit 5.03 Bln Rupees
Jan 24 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
DIVIDEND 26 RUPEES PER SHARE
Q3 CONSOL NET PROFIT 5.03 BILLION RUPEES; IBES EST 5.13 BILLION RUPEES
Q3 CONSOL TOTAL REVENUE FROM OPERATIONS 28.09 BILLION RUPEES; IBES EST 29.92 BILLION RUPEES
Source text: [ID:]
Further company coverage: TORP.NS
(([email protected];;))
Jan 24 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
DIVIDEND 26 RUPEES PER SHARE
Q3 CONSOL NET PROFIT 5.03 BILLION RUPEES; IBES EST 5.13 BILLION RUPEES
Q3 CONSOL TOTAL REVENUE FROM OPERATIONS 28.09 BILLION RUPEES; IBES EST 29.92 BILLION RUPEES
Source text: [ID:]
Further company coverage: TORP.NS
(([email protected];;))
Torrent Pharmaceuticals Issues Commercial Papers Worth 2 Billion Rupees
Dec 26 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
ISSUES COMMERCIAL PAPERS WORTH 2 BILLION RUPEES
Source text: ID:nBSE2DtznC
Further company coverage: TORP.NS
(([email protected];))
Dec 26 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
ISSUES COMMERCIAL PAPERS WORTH 2 BILLION RUPEES
Source text: ID:nBSE2DtznC
Further company coverage: TORP.NS
(([email protected];))
India's Torrent Pharma rises on deal to buy diabetes treatment brands
** Shares of drugmaker Torrent Pharma TORP.NS climb 3% to 3,455 rupees in early trade
** Co says it will acquire three diabetes treatment brands - Cospiaq, Cospiaq Met and Xilingio - from German biopharmaceuticals firm Boehringer Ingelheim
** Acquisition to be completed in March 2025
** TORP, which makes diseases for long-time illnesses like diabetes and thyroid, has been marketing these brands since 2022 under a co-marketing agreement with Boehringer
** Analysts rate TORP, rivals Mankind Pharma MNKI.NS and Glenmark Pharma GLEN.NS at "buy" - LSEG data
** TORP's ~50% YTD gain smaller than GLEN's 81% climb but bigger than MNKI's 31% rise
(Reporting by Kashish Tandon in Bengaluru)
** Shares of drugmaker Torrent Pharma TORP.NS climb 3% to 3,455 rupees in early trade
** Co says it will acquire three diabetes treatment brands - Cospiaq, Cospiaq Met and Xilingio - from German biopharmaceuticals firm Boehringer Ingelheim
** Acquisition to be completed in March 2025
** TORP, which makes diseases for long-time illnesses like diabetes and thyroid, has been marketing these brands since 2022 under a co-marketing agreement with Boehringer
** Analysts rate TORP, rivals Mankind Pharma MNKI.NS and Glenmark Pharma GLEN.NS at "buy" - LSEG data
** TORP's ~50% YTD gain smaller than GLEN's 81% climb but bigger than MNKI's 31% rise
(Reporting by Kashish Tandon in Bengaluru)
Torrent Pharma Enters Into Agreement With Boehringer Ingelheim To Acquire 3 Anti-Diabetes Brands
Dec 4 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
ENTERS INTO AGREEMENT WITH BOEHRINGER INGELHEIM TO ACQUIRE 3 ANTI-DIABETES BRANDS
ACQUISITION EXPECTED TO COMPLETE IN MARCH 2025
Source text: ID:nBSEbDW2f4
Further company coverage: TORP.NS
(([email protected];))
Dec 4 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
ENTERS INTO AGREEMENT WITH BOEHRINGER INGELHEIM TO ACQUIRE 3 ANTI-DIABETES BRANDS
ACQUISITION EXPECTED TO COMPLETE IN MARCH 2025
Source text: ID:nBSEbDW2f4
Further company coverage: TORP.NS
(([email protected];))
India's Torrent Pharmaceuticals rises; USFDA inspection at facility ends
** Shares of Torrent Pharmaceuticals Ltd TORP.NS rise as much as 2.7% to 3,184.75 rupees
** The pharma co says United States Food and Drug Administration (USFDA) has issued establishment inspection report with voluntary action indicated classification for Pithampur manufacturing facility
** Adds that inspection has been successfully closed by the FDA
** Stock on track to snap five weeks of losses
** Mean rating of 27 brokerages rating the stock is "buy"; their median PT is 3,589 rupees - LSEG data
** TORP stock has climbed 2.2% so far this week, adding to YTD gains of 37.8%
(Reporting by Meenakshi Maidas in Bengaluru)
(([email protected];))
** Shares of Torrent Pharmaceuticals Ltd TORP.NS rise as much as 2.7% to 3,184.75 rupees
** The pharma co says United States Food and Drug Administration (USFDA) has issued establishment inspection report with voluntary action indicated classification for Pithampur manufacturing facility
** Adds that inspection has been successfully closed by the FDA
** Stock on track to snap five weeks of losses
** Mean rating of 27 brokerages rating the stock is "buy"; their median PT is 3,589 rupees - LSEG data
** TORP stock has climbed 2.2% so far this week, adding to YTD gains of 37.8%
(Reporting by Meenakshi Maidas in Bengaluru)
(([email protected];))
India's Torrent Pharma falls on block deals at discount
** Shares of Torrent Pharmaceuticals TORP.NS fall as much as 4.1% to 3,084.80 rupees, lowest since July 25
** More than 449,000 shares change hands in nine block deals at 3,094.40-3,125.25 rupees each -LSEG data
** Prices at a discount to stock's last close of 3,215.65 rupees
** Broadcaster ET Now on Tuesday reported TORP promoters to sell 2.9% stake via block deals
** Stock among top losers in Nifty pharma index .NIPHARM which is down 1.3%
** Over 2 mln shares traded, 6x of 30-day avg and most active session since Sept 2023
** Stock up 36% YTD vs 33% gain in pharma index
(Reporting by Ashish Chandra in Bengaluru)
(([email protected] (+91 7982114624))
** Shares of Torrent Pharmaceuticals TORP.NS fall as much as 4.1% to 3,084.80 rupees, lowest since July 25
** More than 449,000 shares change hands in nine block deals at 3,094.40-3,125.25 rupees each -LSEG data
** Prices at a discount to stock's last close of 3,215.65 rupees
** Broadcaster ET Now on Tuesday reported TORP promoters to sell 2.9% stake via block deals
** Stock among top losers in Nifty pharma index .NIPHARM which is down 1.3%
** Over 2 mln shares traded, 6x of 30-day avg and most active session since Sept 2023
** Stock up 36% YTD vs 33% gain in pharma index
(Reporting by Ashish Chandra in Bengaluru)
(([email protected] (+91 7982114624))
Torrent Pharma Promoter To Sell Upto 2.9% Stake Via Block Deals On Oct 30 - ET Now
Oct 29 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
TORRENT PHARMA PROMOTER TO SELL UPTO 2.9% STAKE VIA BLOCK DEALS ON OCT 30 - ET NOW
Source text: [ID:]
Further company coverage: TORP.NS
(([email protected];;))
Oct 29 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
TORRENT PHARMA PROMOTER TO SELL UPTO 2.9% STAKE VIA BLOCK DEALS ON OCT 30 - ET NOW
Source text: [ID:]
Further company coverage: TORP.NS
(([email protected];;))
India's Torrent Pharmaceuticals falls after Q2 profit miss
** Shares of Torrent Pharmaceuticals TORP.NS fall 2.4% to 3,350 rupees
** The pharmaceuticals company's Q2 consol net profit and revenue missed analysts' estimates, per data compiled by LSEG
** Smaller-than-expected profit due to shutdown of an insulin manufacturing facility
** Q2 consol net profit up 17.4% Y/Y, rev rises 8.6% Y/Y
** Trading vols at 384,205, 1.3X the 30-day average
** TORP up ~45% YTD
(Reporting by Vijay Malkar)
(([email protected];))
** Shares of Torrent Pharmaceuticals TORP.NS fall 2.4% to 3,350 rupees
** The pharmaceuticals company's Q2 consol net profit and revenue missed analysts' estimates, per data compiled by LSEG
** Smaller-than-expected profit due to shutdown of an insulin manufacturing facility
** Q2 consol net profit up 17.4% Y/Y, rev rises 8.6% Y/Y
** Trading vols at 384,205, 1.3X the 30-day average
** TORP up ~45% YTD
(Reporting by Vijay Malkar)
(([email protected];))
Torrent Pharmaceuticals Q2 Consol Net Profit 4.53 Bln Rupees
Oct 25 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
Q2 CONSOL NET PROFIT 4.53 BILLION RUPEES; IBES EST 4.97 BILLION RUPEES
Q2 CONSOL TOTAL REVENUE FROM OPERATIONS 28.89 BILLION RUPEES; IBES EST 29.78 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: TORP.NS
(([email protected];;))
Oct 25 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
Q2 CONSOL NET PROFIT 4.53 BILLION RUPEES; IBES EST 4.97 BILLION RUPEES
Q2 CONSOL TOTAL REVENUE FROM OPERATIONS 28.89 BILLION RUPEES; IBES EST 29.78 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: TORP.NS
(([email protected];;))
Torrent Pharma Incorporated Unit Namely Torrent Pharmaceuticals Chile SpA
Sept 26 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
INCORPORATED UNIT NAMELY TORRENT PHARMACEUTICALS CHILE SPA
Source text for Eikon: ID:nBSE7djQ49
Further company coverage: TORP.NS
(([email protected];;))
Sept 26 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:
INCORPORATED UNIT NAMELY TORRENT PHARMACEUTICALS CHILE SPA
Source text for Eikon: ID:nBSE7djQ49
Further company coverage: TORP.NS
(([email protected];;))
India's Torrent Pharma gains after USFDA's routine inspection
** Torrent Pharmaceuticals TORP.NS gains 2.9%, on track to snap 3 sessions of losses
** Co says U.S. FDA conducted routine inspection of manufacturing facility in Madhya Pradesh from Sept. 16-20
** Adds agency issued form 483 after inspection with one procedural observation
** More than 260,000 shares traded in stock's busiest day this week
** Avg rating of 27 brokerages is "buy"; median PT is 3,295 rupees vs current price of 3450.75 rupees - LSEG
** TORP adds 49.4% YTD vs a 36.4% gain in Nifty pharma index .NIPHARM
(Reporting by Meenakshi Maidas in Bengaluru)
(([email protected];))
** Torrent Pharmaceuticals TORP.NS gains 2.9%, on track to snap 3 sessions of losses
** Co says U.S. FDA conducted routine inspection of manufacturing facility in Madhya Pradesh from Sept. 16-20
** Adds agency issued form 483 after inspection with one procedural observation
** More than 260,000 shares traded in stock's busiest day this week
** Avg rating of 27 brokerages is "buy"; median PT is 3,295 rupees vs current price of 3450.75 rupees - LSEG
** TORP adds 49.4% YTD vs a 36.4% gain in Nifty pharma index .NIPHARM
(Reporting by Meenakshi Maidas in Bengaluru)
(([email protected];))
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Bonus
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
More Large Cap Ideas
See similar 'Large' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Torrent Pharma do?
Torrent Pharmaceuticals is engaged in manufacturing, developing and marketing of generic pharmaceutical formulations. The company is a leading player in the areas of Cardiovascular and Central Nervous Systems, having achieved significant presence in segments of Nephrology, Oncology, Pulmonology, Gynecology and Pediatric treatments.The company operates in two key business segments - Branded Generics (BGx) and Generics (Gx). Each segment plays a pivotal role in its growth strategy, catering to diverse therapeutic needs across different regions.
Who are the competitors of Torrent Pharma?
Torrent Pharma major competitors are Cipla, Dr. Reddy's Lab, Mankind Pharma, Zydus Lifesciences, Lupin, Alkem Laboratories, Aurobindo Pharma. Market Cap of Torrent Pharma is ₹1,21,862 Crs. While the median market cap of its peers are ₹98,782 Crs.
Is Torrent Pharma financially stable compared to its competitors?
Torrent Pharma seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Torrent Pharma pay decent dividends?
The company seems to pay a good stable dividend. Torrent Pharma latest dividend payout ratio is 56.67% and 3yr average dividend payout ratio is 57.89%
How has Torrent Pharma allocated its funds?
Companies resources are allocated to majorly unproductive assets like Capital Work in Progress, Inventory, Accounts Receivable, Short Term Loans & Advances
How strong is Torrent Pharma balance sheet?
Balance sheet of Torrent Pharma is strong. But short term working capital might become an issue for this company.
Is the profitablity of Torrent Pharma improving?
Yes, profit is increasing. The profit of Torrent Pharma is ₹2,002 Crs for TTM, ₹1,911 Crs for Mar 2025 and ₹1,656 Crs for Mar 2024.
Is the debt of Torrent Pharma increasing or decreasing?
The net debt of Torrent Pharma is decreasing. Latest net debt of Torrent Pharma is ₹1,868 Crs as of Mar-25. This is less than Mar-24 when it was ₹2,260 Crs.
Is Torrent Pharma stock expensive?
Yes, Torrent Pharma is expensive. Latest PE of Torrent Pharma is 60.87, while 3 year average PE is 54.94. Also latest EV/EBITDA of Torrent Pharma is 32.3 while 3yr average is 25.46.
Has the share price of Torrent Pharma grown faster than its competition?
Torrent Pharma has given better returns compared to its competitors. Torrent Pharma has grown at ~36.67% over the last 2yrs while peers have grown at a median rate of 16.48%
Is the promoter bullish about Torrent Pharma?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Torrent Pharma is 68.31% and last quarter promoter holding is 68.31%.
Are mutual funds buying/selling Torrent Pharma?
The mutual fund holding of Torrent Pharma is decreasing. The current mutual fund holding in Torrent Pharma is 4.95% while previous quarter holding is 5.03%.